A New First-Line Option for Advanced Triple-Negative Breast Cancer: What the ASCENT-03 Trial Means for Patients

Table of Contents

• Key Points
• What Is Triple-Negative Breast Cancer?
• Why This Study Was Needed
• What Is Sacituzumab Govitecan?
• How the Study Was Designed
• Who Participated in the Trial
• Key Finding: More Time Before the Cancer Grew
• Key Finding: Tumor Shrinkage and How Long It Lasted
• Key Finding: Overall Survival
• Side Effects and Safety
• Clinical Implications: What This Means for Patients
• Limitations of the Study
• Recommendations for Patients
• Frequently Asked Questions
• Source Information

Key Points

• In the ASCENT-03 trial, sacituzumab govitecan delayed cancer growth longer than chemotherapy in advanced triple-negative breast cancer patients who cannot take immunotherapy.
• Median progression-free survival was 9.7 months with sacituzumab govitecan vs 6.9 months with chemotherapy, a 38% lower risk of progression or death.
• Responses lasted longer with sacituzumab govitecan: median 12.2 months vs 7.2 months with chemotherapy, though response rates were similar.
• Fewer patients stopped sacituzumab govitecan due to side effects (4% vs 12%), but neutropenia and diarrhea were common severe side effects.
• Overall survival data were not mature; 82% of chemotherapy patients later received sacituzumab govitecan, which may affect survival comparisons.

What Is Triple-Negative Breast Cancer?

Triple-negative breast cancer is an aggressive subtype of breast cancer. It is "triple-negative" because the tumor cells lack three key features that are common in other breast cancers: estrogen receptor (ER), progesterone receptor (PR), and overexpression of human epidermal growth factor receptor 2 (HER2). This means the cancer does not respond to hormonal therapies or to drugs that target HER2.

About 1 in 10 to 1 in 7 breast cancers (10 to 15%) are triple-negative. This subtype carries a poor outlook. Only about 15% of patients with metastatic triple-negative breast cancer — cancer that has spread beyond the breast — survive 5 years after diagnosis.

The cancer's PD-L1 status matters for treatment decisions. PD-L1 is a protein that helps tumors hide from the immune system. The combined positive score (CPS) measures PD-L1 staining. It counts PD-L1-staining tumor cells, lymphocytes, and macrophages, divided by the total number of viable tumor cells, multiplied by 100. Tumors with a CPS below 10 are considered PD-L1-negative. About 60% of metastatic triple-negative breast cancers are PD-L1-negative.

Why This Study Was Needed

Patients with advanced triple-negative breast cancer who have not received prior treatment for advanced disease have had limited options. For patients with PD-L1-negative tumors, the only standard first-line treatment has been chemotherapy. For patients with PD-L1-positive tumors (CPS of 10 or higher), guidelines recommend chemotherapy combined with immune checkpoint inhibitors — drugs that release the immune system's brakes by blocking PD-1 or PD-L1.

Some patients cannot take these immunotherapy drugs. This includes patients with PD-L1-positive tumors whose cancer returned after receiving a PD-1 or PD-L1 inhibitor earlier (in the neoadjuvant or adjuvant setting, meaning before or after surgery). It also includes patients with other medical conditions that prevent them from safely receiving a checkpoint inhibitor.

Other targeted options are limited. Poly(ADP-ribose) polymerase (PARP) inhibitors are only approved for the small group of patients with inherited BRCA1 or BRCA2 gene mutations. Chemotherapy alone is associated with short survival.

Real-world studies show an urgent need for better first-line treatment. Approximately 50% of patients with this aggressive disease never receive a second line of treatment. In about 30% of cases, that is because the patient dies before a second treatment can begin.

What Is Sacituzumab Govitecan?

Sacituzumab govitecan is an antibody-drug conjugate (ADC). It is a "smart bomb" therapy that combines an antibody with a potent chemotherapy drug. The antibody targets trophoblast cell-surface antigen 2 (Trop-2), a protein that is highly expressed on triple-negative breast cancer cells. Once the antibody binds to the cancer cell, the drug is released inside the cell.

The drug portion is a potent topoisomerase I inhibitor, an enzyme blocker that damages cancer cell DNA and triggers cell death. It is attached through a hydrolyzable linker at a high drug-to-antibody ratio, meaning each antibody carries many drug molecules. This design aims to deliver a large dose of chemotherapy directly to the tumor while limiting damage to healthy tissue.

Sacituzumab govitecan has an established track record in later lines of therapy. In the earlier ASCENT trial, it significantly improved progression-free survival compared with chemotherapy in patients who had already received prior treatment. It is approved in multiple countries for metastatic triple-negative breast cancer after at least two previous systemic therapies (or at least one in the metastatic setting).

The ASCENT-04 trial also showed that sacituzumab govitecan combined with pembrolizumab (an immunotherapy drug) was superior to chemotherapy plus pembrolizumab as first-line treatment. The current study, ASCENT-03, asked a different question: How does sacituzumab govitecan alone compare with chemotherapy as a first-line treatment for patients who cannot take immunotherapy at all?

How the Study Was Designed

The ASCENT-03 trial was an international, phase 3, open-label, randomized study. It took place at 229 sites in 30 countries. "Open-label" means both patients and doctors knew which treatment was being given. "Phase 3" means it was a large, late-stage trial designed to confirm whether one treatment is better than the standard of care.

Adults were eligible if they had locally advanced, unresectable (not removable by surgery) or metastatic triple-negative breast cancer. They must not have received any prior systemic therapy for advanced disease. All patients had to be ineligible for PD-1 or PD-L1 inhibitors. That included patients with PD-L1-negative tumors (CPS below 10) and patients with PD-L1-positive tumors (CPS of 10 or higher) who had either already received a checkpoint inhibitor in the neoadjuvant or adjuvant setting or had a coexisting condition that ruled out these drugs.

Triple-negative status was confirmed centrally before enrollment, using strict criteria from the American Society of Clinical Oncology and the College of American Pathologists. These criteria define triple-negative disease as less than 1% of tumor cells positive for ER or PR and a HER2 result of 0, 1+, or 2+ with a negative in situ hybridization test. Tumor PD-L1 status by CPS was also confirmed centrally.

Patients were randomly assigned in a 1:1 ratio to one of two treatment groups:

• Sacituzumab govitecan: given intravenously at a dose of 10 mg per kilogram of body weight on days 1 and 8 of a 21-day cycle.
• Chemotherapy (chosen before randomization, at the doctor's discretion):
  • Paclitaxel at 90 mg per square meter of body-surface area on days 1, 8, and 15 of a 28-day cycle, or
  • Nanoparticle albumin-bound paclitaxel at 100 mg per square meter on the same schedule, or
  • Gemcitabine at 1000 mg per square meter plus carboplatin (dosed to reach an area under the concentration-time curve of 2 mg per milliliter per minute) on days 1 and 8 of a 21-day cycle.

All treatments were given intravenously. Patients were stratified at randomization by two factors: disease status (metastatic at initial diagnosis, recurrence within 6 to 12 months after curative-intent treatment, or recurrence more than 12 months after curative-intent treatment) and geographic region (Canada, the United States, or Western Europe vs. the rest of the world).

Treatment continued until disease progression was confirmed by blinded independent central review (BICR — an independent panel that did not know which treatment each patient received), until unacceptable side effects occurred, until the patient withdrew consent, or until death. Patients in the chemotherapy group whose cancer progressed could cross over and receive sacituzumab govitecan if they met eligibility criteria.

The primary end point (the main question the trial was designed to answer) was progression-free survival: the time from randomization to disease progression or death, whichever came first, as assessed by blinded review using standard criteria called RECIST version 1.1. Secondary end points included overall survival, objective response (complete or partial tumor shrinkage confirmed by blinded review), duration of response, time to response, safety, and patient-reported outcomes (to be reported separately).

Tumor scans (CT or MRI) were performed every 6 weeks for the first year, then every 12 weeks until progression or the start of new therapy. Adverse events were coded using the Medical Dictionary for Regulatory Activities version 27.1 and graded for severity per the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.

The trial planned to enroll about 540 patients. The final analysis of progression-free survival was planned after about 352 events (progression or death) had occurred. This gave the study more than 95% power to detect a hazard ratio of 0.65. Overall survival was to be analyzed at the same time, with a nominal two-sided alpha of 0.01% spent even without formal hypothesis testing, provided progression-free survival showed a significant difference.

Who Participated in the Trial

Between October 27, 2022, and July 29, 2024, a total of 558 patients were enrolled and randomly assigned: 279 to sacituzumab govitecan and 279 to chemotherapy. Among those in the chemotherapy group, 56% were selected to receive a taxane (paclitaxel or nab-paclitaxel) and 44% to receive gemcitabine plus carboplatin.

The two groups were well balanced at the start of the trial:

• Age: median 56 years (range 28 to 84) in the sacituzumab govitecan group vs. 54 years (range 23 to 86) in the chemotherapy group. About 23% vs. 28% were age 65 or older.
• Sex: 278 (>99%) vs. 277 (99%) were female.
• Race: White 64% in both groups; Asian 24% vs. 23%; Black 4% vs. 3%; other or not specified 9% vs. 10%.
• ECOG performance status (a measure of daily function, where 0 is fully active and 1 is restricted but ambulatory): score 0 in 66% vs. 67%; score 1 in 34% vs. 33%.
• PD-L1 status: 277 of 279 patients (99%) in the sacituzumab govitecan group and 278 of 279 (>99%) in the chemotherapy group had PD-L1-negative tumors.
• Disease status: metastatic at initial diagnosis in 87 patients (31%) vs. 88 (32%); recurrence within 6 to 12 months after curative-intent treatment in 58 (21%) vs. 57 (20%); recurrence more than 12 months after curative-intent treatment in 134 (48%) in each group.
• Common metastatic sites: lymph nodes (64% vs. 65%), lung (59% vs. 61%), bone (34% vs. 31%), liver (29% vs. 26%), brain (5% in both groups).
• Prior therapy: 58% in both groups had previously received a taxane; 18% vs. 20% had received capecitabine; 18% vs. 18% had received platinum agents; 5% vs. 4% had received PD-1 or PD-L1 inhibitors.
• Time from diagnosis of metastatic disease to randomization: median 1.9 months in both groups.

The trial population was generally representative of patients with metastatic triple-negative breast cancer.

Key Finding: More Time Before the Cancer Grew

The most important result was clear: sacituzumab govitecan kept the cancer from growing for longer than chemotherapy. At the time of the primary analysis, 349 primary end-point events (disease progression or death) had occurred.

The median progression-free survival (the time by which half of patients had experienced progression or death) was:

• 9.7 months with sacituzumab govitecan (95% confidence interval [CI], 8.1 to 11.1), compared with
• 6.9 months with chemotherapy (95% CI, 5.6 to 8.2).

That is a median difference of 2.8 months. The stratified hazard ratio for disease progression or death was 0.62 (95% CI, 0.50 to 0.77; P<0.001). In plain terms, patients taking sacituzumab govitecan had a 38% lower risk of their cancer progressing or dying during the study period compared with those taking chemotherapy.

The result was statistically highly significant. P<0.001 means the chance that this difference happened by random luck is less than 0.1%. The confidence interval (0.50 to 0.77) shows the true effect likely lies somewhere in this range — and the entire range favors sacituzumab govitecan.

The results held up when assessed by the investigators themselves, not just by the blinded central review. Investigator-assessed median progression-free survival was 9.6 months (95% CI, 8.3 to 10.6) with sacituzumab govitecan vs. 6.8 months (95% CI, 5.6 to 7.2) with chemotherapy, a hazard ratio of 0.64 (95% CI, 0.52 to 0.79). The consistency between the two assessments strengthens confidence in the findings.

Progression-free survival benefits appeared across predefined patient subgroups, including different disease-status categories and geographic regions. At the data-cutoff date (April 2, 2025), the median follow-up was 13.2 months (range, less than 0.1 to 29.2). At that point, 75 patients (27%) in the sacituzumab govitecan group and 39 (14%) in the chemotherapy group were still receiving their assigned treatment.

The most common reasons for stopping treatment were disease progression (58% in the sacituzumab govitecan group vs. 70% in the chemotherapy group), side effects (4% vs. 8%), and patient decision (6% in each group).

Key Finding: Tumor Shrinkage and How Long It Lasted

The proportion of patients whose tumors shrank (the objective response rate) was similar in both groups. A confirmed objective response — either a complete response (all detectable cancer gone) or a partial response (significant shrinkage) — occurred in:

• 48% of patients who received sacituzumab govitecan (95% CI, 42 to 54), vs.
• 46% of patients who received chemotherapy (95% CI, 40 to 52).

A complete response was confirmed in 20 patients (7%) in the sacituzumab govitecan group and 15 (5%) in the chemotherapy group. So about 1 in 14 patients on sacituzumab govitecan had all detectable cancer disappear, compared with about 1 in 20 on chemotherapy.

The more striking difference was in how long the response lasted. Among patients with a confirmed complete or partial response, the median duration of response was:

• 12.2 months with sacituzumab govitecan (95% CI, 9.7 to 13.8), vs.
• 7.2 months with chemotherapy (95% CI, 5.7 to 8.4).

That is a difference of 5.0 months — responses lasted substantially longer with sacituzumab govitecan even though the response rates were similar. The median time to response was the same in both groups: 1.6 months (range 0.7 to 16.7 with sacituzumab govitecan vs. 0.9 to 6.8 with chemotherapy). Tumors that responded began to shrink quickly in both groups, but the effects of sacituzumab govitecan endured longer.

Key Finding: Overall Survival

At the time of the progression-free survival analysis, overall survival data were not yet mature. The data were only at 37% maturity — meaning most patients were still alive, so the final survival picture is not yet known.

The median overall survival at this early point was 21.5 months (95% CI, 17.7 to not reached) in the sacituzumab govitecan group and 20.2 months (95% CI, 18.2 to not reached) in the chemotherapy group. Because the data are not mature, these numbers should be read as preliminary, and no formal statistical conclusion can yet be drawn.

One important factor complicates the survival analysis: treatment crossover. Overall, 305 patients (55%) received a subsequent line of therapy after stopping trial treatment — 126 (45%) in the sacituzumab govitecan group and 179 (64%) in the chemotherapy group. Of the 179 chemotherapy patients who received any subsequent treatment, 147 (82%) went on to receive sacituzumab govitecan, either through the protocol-specified crossover phase or through commercial access.

This high crossover rate means many patients in the chemotherapy group eventually received the experimental drug. That can dilute any difference in overall survival between the two groups. The trial continues to follow patients, and a longer follow-up will provide more definitive survival information.

Side Effects and Safety

Both treatments caused frequent side effects. The safety analysis included 275 patients in the sacituzumab govitecan group and 276 in the chemotherapy group who received at least one dose of their assigned treatment.

The median duration of treatment was 8.3 months (range, less than 0.1 to 28.7) with sacituzumab govitecan. By comparison, it was 6.3 months (range, less than 0.1 to 24.2) with a taxane and 5.8 months (range, less than 0.1 to 23.1) with gemcitabine plus carboplatin.

Overall side-effect rates were similar:

• Any-grade adverse events: 273 patients (99%) with sacituzumab govitecan vs. 269 (97%) with chemotherapy.
• Grade 3 or higher adverse events (severe, medically significant, or life-threatening): 181 patients (66%) with sacituzumab govitecan vs. 171 (62%) with chemotherapy.

The most frequent severe side effects differed somewhat between the groups. With sacituzumab govitecan, the most common grade 3+ events were:

• Neutropenia (low white blood cell counts, increasing infection risk): 43%
• Diarrhea: 9%
• Leukopenia (low overall white blood cell count): 7%

With chemotherapy, the most common grade 3+ events were:

• Neutropenia: 41%
• Anemia (low red blood cell counts, causing fatigue): 16%
• Leukopenia: 13%

Notably, fewer patients stopped treatment because of side effects with sacituzumab govitecan. Adverse events led to discontinuation in 10 patients (4%) in the sacituzumab govitecan group vs. 33 patients (12%) in the chemotherapy group. That is a threefold difference in favor of sacituzumab govitecan.

There were 7 deaths in the sacituzumab govitecan group due to adverse events. Investigators judged 6 of these to be related to trial treatment: 4 cases of sepsis (a severe, whole-body infection response), 1 case of neutropenic colitis (inflammation of the colon during severe neutropenia), and 1 case of pneumonia. One additional death from acute respiratory failure was judged unrelated to treatment. All treatment-related deaths in the sacituzumab govitecan group were due to infections.

Clinical Implications: What This Means for Patients

This is the first phase 3 trial to show that an antibody-drug conjugate is superior to chemotherapy as a first-line treatment for advanced triple-negative breast cancer in patients who cannot receive PD-1 or PD-L1 inhibitors. For this specific and substantial group of patients, sacituzumab govitecan offers a new standard-of-care option.

The practical benefits for patients are measurable:

• A median of 9.7 months before cancer progression, vs. 6.9 months with chemotherapy — about 2.8 additional months, and a 38% lower relative risk of progression or death.
• Responses that lasted a median of 12.2 months vs. 7.2 months — about 5 additional months of tumor control for those whose cancer shrank.
• A lower rate of treatment discontinuation due to side effects (4% vs. 12%), meaning more patients could stay on therapy.

The side-effect profile is manageable but requires vigilance. The most common severe side effect with sacituzumab govitecan is neutropenia, affecting 43% of patients — about 2 in 5. This requires regular blood count monitoring and may require supportive treatments such as growth factors to boost white blood cells. Diarrhea occurred in 9% of patients at grade 3 or higher and needs early, aggressive management to prevent dehydration and more serious complications.

Because treatment-related deaths were infection-related, patients and care teams should watch closely for fever, chills, or other signs of infection, especially during periods of low white blood cell counts. Prompt medical attention is essential.

The findings also add to the evidence base for sacituzumab govitecan across the treatment spectrum. It is already approved in later lines of therapy. The ASCENT-04 trial showed benefit when combined with pembrolizumab as first-line treatment. ASCENT-03 now demonstrates benefit as a single agent in first-line patients who are not candidates for checkpoint inhibitors.

Limitations of the Study

No single trial answers every question. Several limitations of ASCENT-03 should be considered:

• Open-label design: Both patients and doctors knew which treatment was being given. This can introduce bias, though the primary end point was assessed by a blinded independent review panel, which reduces this concern.
• Immature overall survival data: Survival data were only 37% mature at the time of analysis. The median survival estimates (21.5 vs. 20.2 months) are preliminary and could change with longer follow-up.
• High crossover: 82% of chemotherapy patients who received further treatment later received sacituzumab govitecan. This is ethically appropriate and good for patients, but it can obscure a true survival benefit by "contaminating" the chemotherapy group with the experimental drug.
• Limited PD-L1-positive representation: 99% of enrolled patients had PD-L1-negative tumors. While this reflects the study's focus on patients not eligible for checkpoint inhibitors, it means the trial provides little direct evidence about sacituzumab govitecan alone in PD-L1-positive patients who can take immunotherapy.
• Short median follow-up: At 13.2 months, the follow-up is relatively brief for a chronic disease like metastatic breast cancer. Longer-term durability of responses and late side effects are not yet fully characterized.
• Patient-reported outcomes pending: Quality-of-life data from this trial will be reported separately and were not included in this publication.

Recommendations for Patients

If you or a loved one has advanced triple-negative breast cancer, this study provides important new information to discuss with your oncology team:

1. Know your PD-L1 status and your eligibility for immunotherapy. This trial specifically studied patients who could not receive PD-1 or PD-L1 checkpoint inhibitors. If immunotherapy is an option for you, the standard of care may still include it, and ASCENT-04 has separately studied the combination of sacituzumab govitecan with pembrolizumab.
2. Ask whether sacituzumab govitecan is appropriate as a first-line treatment. For patients who are not candidates for checkpoint inhibitors, this trial provides strong evidence that sacituzumab govitecan should be considered as an initial therapy rather than waiting until later lines.
3. Plan for monitoring. If you receive sacituzumab govitecan, expect regular blood tests to check your white blood cell counts. Neutropenia is common (affecting about 2 in 5 patients) and increases infection risk. Your care team may use medications called growth factors to reduce this risk.
4. Take diarrhea seriously. Severe diarrhea occurred in about 1 in 11 patients on sacituzumab govitecan. Ask your care team in advance about anti-diarrheal medications, when to call the clinic, and how to stay hydrated.
5. Know the signs of infection. All treatment-related deaths in the sacituzumab govitecan group were due to infections. If you develop a fever, chills, sore throat, or other signs of infection, seek medical attention promptly — do not wait.
6. Ask about clinical trials. This study was conducted at 229 sites in 30 countries, and the ASCENT-03 trial is registered under the number NCT05382299. Ask your oncologist whether any relevant trials are available at your center.

Frequently Asked Questions

What is sacituzumab govitecan and how does it work?

Sacituzumab govitecan is an antibody-drug conjugate, sometimes called a 'smart bomb' therapy. It combines an antibody that targets a protein on triple-negative breast cancer cells with a potent chemotherapy drug. The antibody delivers the drug directly into the cancer cell, damaging its DNA and causing cell death, while limiting harm to healthy tissue.

Who was eligible for the ASCENT-03 trial?

Adults with advanced triple-negative breast cancer that had not been treated with systemic therapy for advanced disease were eligible. All patients had to be ineligible for PD-1 or PD-L1 inhibitors, meaning they had PD-L1-negative tumors or had already received a checkpoint inhibitor earlier, or had a medical condition preventing their use.

What were the main results of the ASCENT-03 trial?

In the trial, patients receiving sacituzumab govitecan lived a median of 9.7 months without cancer worsening, compared to 6.9 months with chemotherapy. This was a 38% reduction in the risk of progression or death. Responses lasted longer with sacituzumab govitecan, but overall survival data were not yet mature.

What side effects should I expect with sacituzumab govitecan?

The most common severe side effect was neutropenia, affecting about 43% of patients, which increases infection risk. Diarrhea occurred in 9% at grade 3 or higher. Other side effects included low white blood cell counts. Fewer patients stopped treatment due to side effects compared to chemotherapy (4% vs 12%).

Is sacituzumab govitecan approved for first-line treatment?

This trial provides strong evidence that sacituzumab govitecan should be considered as a first-line treatment for patients with advanced triple-negative breast cancer who cannot receive immunotherapy. It is already approved in later lines of therapy. Discuss with your oncology team whether it is appropriate for your situation.

What should I watch for if I take sacituzumab govitecan?

Watch for signs of infection like fever, chills, or sore throat, especially during low white blood cell counts. Take diarrhea seriously and ask about anti-diarrheal medications and hydration. Regular blood tests are needed to monitor your counts. Seek prompt medical attention for any infection signs.

Should I get a second opinion before starting sacituzumab govitecan for advanced triple-negative breast cancer?

A second opinion can help confirm that sacituzumab govitecan is the right first-line choice for you, especially since this trial studied patients who cannot take immunotherapy. The study showed it delayed cancer growth by a median of 9.7 months versus 6.9 months with chemotherapy, with fewer patients stopping due to side effects. A second opinion can also verify your PD-L1 status and ensure no other options, like clinical trials, are more appropriate. Diagnostic Detectives Network provides independent expert second opinions.

Source Information

This patient-friendly article is based on peer-reviewed research.

Original article title: Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer

Journal: The New England Journal of Medicine, 2025; volume 393, pages 1912-1925.

Publication details: Published October 19, 2025. DOI: 10.1056/NEJMoa2511734.

Funding: Gilead Sciences. ClinicalTrials.gov number: NCT05382299.

This content is provided for educational purposes only and is not a substitute for professional medical advice. Always discuss treatment decisions with your oncology care team.